What Is Valproic Acid, and How Did It Become a Subject of Interest in Hair Growth and Alopecia Research?

Valproic acid is not a new or experimental substance. Its anticonvulsant activity was discovered in 1962, it was first marketed in France in 1967, and it was approved in the United States in 1978, primarily for neurological and psychiatric conditions. Health authorities such as the U.S. Food and Drug Administration recognize valproic acid as an anti‑epileptic and mood‑stabilizing medication used in epilepsy, bipolar disorder, and migraine prevention. Its original development had nothing to do with dermatology or cosmetic medicine. However, the interest in valproic acid within hair loss research did not arise from marketing claims, but from observations made in basic biomedical research.

Valproic acid was never designed to promote hair growth, and hair‑related effects were initially treated as biologically incidental. Only after decades of use did researchers document that the drug influences cellular processes that are also relevant to hair follicle behavior. That overlap, rather than clinical success in hair loss patients, is what sparked scientific interest.

How a neurological drug affects cells beyond the brain

Valproic acid exerts its primary therapeutic effects by increasing levels of gamma‑aminobutyric acid, commonly abbreviated as GABA. GABA is a naturally occurring chemical messenger that reduces excessive electrical activity in the brain. That mechanism explains its neurological use but not its relevance to hair follicles. The connection lies elsewhere.

A separate and well‑documented property of valproic acid is its ability to inhibit histone deacetylases. These enzymes regulate how tightly DNA is packaged inside cells. When DNA is tightly packed, certain genes are less active; when it is more relaxed, gene activity increases. This form of regulation is known as epigenetic control, meaning it affects gene expression without altering the genetic code itself. Hair follicles depend on precise gene signaling to move between growth, regression, and rest phases. Any compound capable of altering gene activity in skin cells therefore becomes a legitimate object of study, regardless of its original purpose.

Why hair follicles became part of the discussion

Hair follicles are not static structures. They cycle continuously through phases of growth and rest, and this cycling is controlled by signaling pathways inside the skin. One of the most important of these is the Wnt/β‑catenin signaling pathway, which acts as a biological instruction system telling hair follicle cells when to start a growth phase.

Research indexed by PubMed has repeatedly linked impaired Wnt/β‑catenin signaling to androgenetic alopecia, the most common form of hair loss in both men and women. Valproic acid attracted attention because laboratory studies reported that it inhibits glycogen synthase kinase 3β and activates that pathway. At that stage the interest was theoretical rather than clinical: the reasoning was not that valproic acid cured hair loss, but that it interacts with a pathway known to be important for hair follicle activation.

What laboratory studies actually showed

One of the most cited studies linking valproic acid to hair growth mechanisms was published in 2012 by Lee and colleagues in PLoS ONE. It combined two lines of work: topical valproic acid applied to mice, where the authors reported induction of hair regeneration, and human dermal papilla cells — the specialized cells at the base of the follicle that help regulate hair growth — where valproic acid increased alkaline phosphatase activity, a marker associated with the hair‑inducing capacity of those cells.

A 2013 study by Jo and colleagues in the Journal of Dermatological Science took the question a step closer to human tissue, culturing human hair follicles in the laboratory and reporting that valproic acid promoted hair growth in that organ‑culture model.

These findings indicate biological plausibility, not therapeutic effectiveness. Isolated cells and cultured follicles do not replicate the hormonal and immune environment of a living scalp, and laboratory concentrations often differ from what can be safely achieved in real‑world use.

Evidence from animal models and its limits

The mouse work described above is frequently quoted online, and a critical reading is essential. Mouse hair growth cycles differ significantly from human cycles, and mice do not develop androgenetic alopecia the way humans do. Animal studies are useful for understanding mechanisms, but they cannot establish clinical relevance on their own. This limitation is acknowledged within the scientific literature and remains a key reason why enthusiasm has stayed cautious.

Human research and what it does and does not tell us

Human studies on valproic acid and hair loss are scarce and small. The main one is a randomized, double‑blind, placebo‑controlled feasibility study by Jo and colleagues, published in 2014 in the Journal of Dermatology. Men with moderate androgenetic alopecia used either an 8.3% sodium valproate spray or a placebo spray for 24 weeks, with hair count measured by phototrichogram analysis — a technique that measures hair growth through repeated imaging of the same scalp area.

Forty patients enrolled and 27 completed the protocol (15 on valproic acid, 12 on placebo). The mean change in total hair count was higher in the valproic acid group than in the placebo group, and the authors reported the difference as statistically significant (P = 0.047). Adverse events in both groups were described as mostly mild and self‑limited at similar rates, though one participant using the topical spray developed ventricular tachycardia, which the authors judged did not appear related to the spray.

Read critically, this is a single small feasibility trial: 27 completers, no long‑term follow‑up, and no head‑to‑head comparison with established treatments such as minoxidil or finasteride. The authors described topical valproic acid as a potential treatment option requiring further study, not as an established one.

Safety concerns that shape the research narrative

Any discussion of valproic acid must address safety, and one point is directly relevant to readers here: hair loss is itself a recognized adverse effect of oral valproate. A 2019 systematic review and meta‑analysis in Seizure examined the risk of valproic acid‑related alopecia, and shedding on valproate is well described in the psychiatric and neurological literature. Someone taking oral valproate who is losing hair should raise that with their prescriber rather than assume the two are unrelated.

Oral valproic acid also carries well‑documented risks including liver toxicity and severe birth defects, recognized by regulatory bodies including the FDA. Valproate is a known teratogen: it is contraindicated in pregnancy for migraine prevention and is restricted in women of childbearing potential unless other treatments have failed and effective contraception is in place, because of the risk of neural‑tube defects and neurodevelopmental harm. Anyone who is pregnant, may become pregnant, or is breastfeeding should not use valproate products, including topical or compounded ones, without medical advice.

Although topical application is assumed to reduce systemic exposure, that assumption has not been validated by large, long‑term studies. A compound with known systemic risks faces a higher threshold for acceptance in cosmetic or dermatological use, which is part of why valproic acid has not progressed beyond exploratory research in the hair loss field despite more than a decade of investigation.

Talking to a doctor

Valproic acid is a prescription anticonvulsant, not a cosmetic ingredient, and no topical valproate product is approved for hair loss anywhere. Talk to a doctor or pharmacist before starting, stopping or combining valproic acid in any form, including compounded topical preparations — and never change an anticonvulsant or mood‑stabilizer dose on your own, because stopping abruptly can be dangerous.

What readers actually need to know

When evaluating valproic acid as a potential hair growth agent, the key question is not whether it can influence hair‑related pathways, but whether it can do so safely and consistently in humans. Current evidence supports biological activity at the cellular and animal level. Human evidence is limited to one small randomized feasibility trial.

Valproic acid is an example of drug repurposing driven by molecular biology rather than clinical success. Interest in a mechanism does not equal proof of benefit, and the absence of regulatory approval reflects unresolved questions rather than oversight.

Research context and critical synthesis

Between 2012 and 2014, research on valproic acid and hair growth progressed from cell and mouse studies to one small human trial. Methods included in vitro cell culture, human follicle organ culture, animal application models, and short‑term topical use in humans. Evaluation relied on molecular assays, microscopy, and imaging‑based hair measurements. Across studies, consistent criticisms include small sample sizes, lack of long‑term safety data, and uncertain real‑world applicability. Those limitations explain why valproic acid remains a subject of scientific interest rather than a validated treatment for alopecia.

References

Lee, S. H., Yoon, J., Shin, S. H., et al. (2012). Valproic acid induces hair regeneration in murine model and activates alkaline phosphatase activity in human dermal papilla cells. PLoS ONE, 7(4), e34152. https://pubmed.ncbi.nlm.nih.gov/22506014/

Jo, S. J., Choi, S. J., Yoon, S. Y., et al. (2013). Valproic acid promotes human hair growth in in vitro culture model. Journal of Dermatological Science, 72(1), 16–24. https://pubmed.ncbi.nlm.nih.gov/23810771/

Jo, S. J., Shin, H., Park, Y. W., et al. (2014). Topical valproic acid increases the hair count in male patients with androgenetic alopecia: A randomized, comparative, clinical feasibility study using phototrichogram analysis. Journal of Dermatology, 41(4), 285–291. https://pubmed.ncbi.nlm.nih.gov/24533507/

Yang, C., et al. (2019). Risk of valproic acid‑related alopecia: A systematic review and meta‑analysis. Seizure, 69, 61–69. https://pubmed.ncbi.nlm.nih.gov/30981051/